# Pneumocystis jirovecii Pneumonia

Pneumocystis jirovecii pneumonia requires rapid risk-based recognition, respiratory severity assessment, organism-directed testing, and early TMP-SMX. In HIV, hypoxemia determines adjunctive corticosteroid use; in non-HIV immunosuppression, diagnostic uncertainty and the corticosteroid benefit-risk balance require individualized decisions.

**Clinical question:** How should clinicians diagnose, stratify severity, treat, and prevent Pneumocystis jirovecii pneumonia in immunocompromised adults?

Updated: 2026-08-24T16:13:48.774110+00:00

## What matters in practice
- In suspected PJP with significant hypoxemia or respiratory deterioration, obtain oxygenation measurements and respiratory specimens promptly, but begin anti-Pneumocystis therapy when clinical probability is high rather than delaying for bronchoscopy. [4][17]
- BAL PCR substantially increases diagnostic yield over conventional staining, but a positive PCR requires integration with host risk, pulmonary syndrome, imaging, fungal burden, and serum β-D-glucan because colonization occurs. [6][9][15]
- Treat PJP with TMP-SMX using 15–20 mg/kg/day of the trimethoprim component in divided oral or IV doses for 21 days; use IV therapy initially for moderate-to-severe disease or unreliable enteral absorption. [16][17][20]
- For HIV-associated PJP with room-air PaO2 below 70 mm Hg or A-a gradient at least 35 mm Hg, give adjunctive corticosteroids as early as possible, ideally within 72 hours of anti-Pneumocystis treatment. [16][17]
- Do not routinely extrapolate the HIV corticosteroid indication to non-HIV PJP; selected hypoxemic patients may benefit, but evidence does not establish routine use. [17]

## Identify patients who need immediate PJP-directed evaluation and treatment

Severity and host immune context determine whether diagnostic sampling can precede empiric therapy.

Suspect PJP in an immunocompromised patient with progressive dyspnea, nonproductive cough, fever, chest discomfort, and new pulmonary infiltrates. In HIV, illness is usually subacute over days to weeks; non-HIV immunosuppressed patients may deteriorate more fulminantly. Document the immune condition, current and recent immunosuppressive drugs, prior PJP, and TMP-SMX prophylaxis at presentation because these findings alter pretest probability and the urgency of treatment. [11][4]

Assess respiratory severity immediately with room-air pulse oximetry and arterial blood gas when hypoxemia is present or corticosteroid eligibility is being considered. In HIV-associated PJP, oxygen saturation below 92% on room air, PaO2 below 70 mm Hg, or A-a oxygen gradient at least 35 mm Hg identifies hypoxemia relevant to adjunctive corticosteroid treatment. Escalate oxygen support and pursue monitored or intensive care management when oxygen requirements are increasing or respiratory failure is evolving. [17]

Obtain chest imaging and send organism-directed testing early, but do not postpone TMP-SMX in a patient with high clinical probability and clinically important hypoxemia. In immunocompromised patients with pulmonary infiltrates, high-resolution chest CT, bronchoalveolar lavage (BAL), and molecular diagnostics may be required because bacterial, viral, fungal, atypical, and noninfectious processes can coexist or mimic PJP. [4]
- Obtain a room-air ABG when feasible if oxygen saturation is low or adjunctive steroid eligibility is uncertain; calculate the A-a oxygen gradient for HIV-associated disease. [16][17]
- Use high-resolution chest CT when radiography is nondiagnostic or the distribution of infiltrates may help direct BAL sampling. [4]
- Send concurrent testing for alternative pathogens from BAL when bronchoscopy is performed for pulmonary infiltrates in an immunocompromised host. [9]

*Severity findings that change immediate PJP management. [16][17][20]*

| Finding | Interpretation | Immediate action |
| --- | --- | --- |
| Room-air PaO2 <70 mm Hg or A-a gradient ≥35 mm Hg in HIV-associated PJP | Hypoxemic PJP; meets accepted threshold for adjunctive corticosteroids. [16][17] | Start anti-Pneumocystis therapy and adjunctive prednisone promptly, ideally within 72 hours. [16][17] |
| Oxygen saturation <92% on room air | Clinically important hypoxemia in PJP assessment. [17] | Obtain ABG when possible, provide supplemental oxygen, and determine whether PaO2 or A-a gradient meets steroid criteria. [17] |
| Moderate-to-severe disease or inability to use enteral therapy | Initial IV treatment is appropriate. [16][20] | Use IV TMP-SMX and transition to oral therapy after clinical improvement. [16][20] |

## Use PCR with clinical context to distinguish PJP from colonization

PCR is highly sensitive, but detection alone does not establish causation.

BAL PCR is the preferred high-yield respiratory test when a definitive diagnosis is needed and bronchoscopy is safe. In a cohort of immunocompromised patients undergoing BAL for pulmonary infiltrates, PCR diagnosed PJP in 42 of 56 cases compared with 8 of 56 by conventional stains, increasing diagnostic yield 5.4-fold. Direct microscopic identification remains a diagnostic standard, while BAL PCR has become more sensitive than microscopy. [9][15]

Interpret a positive respiratory PCR as PJP only when the host is susceptible and the pulmonary syndrome is compatible. Low-level DNA detection can reflect colonization, whereas higher quantitative PCR burdens support disease. In one study, BAL qPCR of 1,300 copies/mL discriminated definite PJP from colonization with 100% sensitivity and 80% specificity; the threshold for probable PJP versus colonization was lower at 340 copies/mL but less discriminating. These cutoffs are assay- and population-dependent and should not be transferred uncritically between laboratories. [6]

Use serum β-D-glucan as an adjunct rather than a stand-alone PJP test. β-D-glucan concentrations were higher in PJP than colonization in a cohort of immunocompromised patients with pulmonary infiltrates, and combining noninvasive β-D-glucan testing with oral wash PCR has been evaluated in non-HIV immunosuppressed patients. A positive β-D-glucan supports a fungal process in the appropriate clinical setting but does not independently establish Pneumocystis as the cause. [1][6]

Noninvasive sputum or oral-wash PCR can help when BAL is not immediately feasible, but a negative noninvasive result should not exclude PJP in a high-risk patient. In paired-sample prospective data, noninvasive specimens had high specificity but lower ability to exclude disease than invasive samples. Discordant sputum-positive/BAL-negative results also occur; therefore, resolve discordance using specimen quality, timing, fungal burden, imaging, β-D-glucan, and trajectory rather than treating either result as definitive in isolation. [8][15]
- Order BAL PCR plus direct staining or immunofluorescence when bronchoscopy is performed; PCR increases detection relative to stains. [7][9][15]
- Request quantitative PCR values when the laboratory provides them; higher organism burden favors active PJP over colonization. [6][8]
- Pair respiratory PCR with serum β-D-glucan when the diagnosis remains uncertain or a noninvasive approach is needed. [1][6]

### When to perform bronchoscopy

Proceed to bronchoscopy with BAL when a patient has diffuse pulmonary infiltrates and the diagnosis will alter management, when noninvasive testing is nondiagnostic or discordant, or when alternative pathogens must be sought. BAL enables broad microbiologic evaluation in immunocompromised hosts and provides the specimen with the strongest diagnostic performance for PJP PCR. [4][8][9]

*Interpretation of common PJP diagnostic scenarios. [1][6][8][9][15]*

| Test pattern | Most useful interpretation | Next step |
| --- | --- | --- |
| Compatible syndrome plus BAL PCR positive | Strong evidence for PJP, particularly with substantial fungal burden. [6][9] | Treat PJP; integrate β-D-glucan and alternate BAL microbiology if competing diagnoses remain plausible. [1][6][9] |
| Respiratory PCR positive with low fungal burden or atypical syndrome | Colonization remains possible. [6] | Review imaging, β-D-glucan, host risk, and competing diagnoses before assigning causation. [1][6] |
| Noninvasive PCR negative with persistent high clinical probability | Noninvasive sampling does not reliably exclude PJP. [8] | Obtain BAL when feasible and continue empiric therapy if respiratory severity warrants. [4][8][9] |
| Sputum PCR positive but BAL PCR negative | Discordance is documented and requires clinical adjudication. [15] | Assess sampling quality, timing, fungal burden, β-D-glucan, imaging, and alternative diagnoses. [1][15] |

## Select treatment by severity, route, and TMP-SMX tolerance

TMP-SMX is first-line therapy across HIV-associated and non-HIV PJP.

Use TMP-SMX as initial treatment unless a severe contraindication prevents its use. Dose the trimethoprim component at 15–20 mg/kg/day with sulfamethoxazole 75–100 mg/kg/day in three or four divided doses; oral and IV formulations have equivalent bioavailability. Treat for 21 days. For mild-to-moderate disease with intact gastrointestinal absorption, oral TMP-SMX is reasonable; TMP-SMX double-strength, two tablets orally three times daily, is a cited oral regimen. [16][17][20]

Use IV TMP-SMX for moderate-to-severe illness, then convert to oral therapy after clinical improvement. Monitor for myelosuppression, hyperkalemia, acute kidney injury, increased creatinine, transaminase elevation, rash including severe cutaneous reactions, neutropenia, and thrombocytopenia. Follow oxygenation and vital signs for response or early treatment failure while checking renal function, serum potassium, and blood counts during therapy. [17][20][21]

For TMP-SMX intolerance, select an alternative based on severity and contraindications. For mild-to-moderate PJP, options include dapsone plus trimethoprim, clindamycin plus primaquine, or atovaquone; atovaquone is less effective than TMP-SMX. For moderate-to-severe disease, clindamycin-primaquine or IV pentamidine are alternatives. Do not use aerosolized pentamidine to treat active PJP. [17][19]

Before primaquine, screen for G6PD deficiency because primaquine can cause hemolysis and methemoglobinemia in deficient patients. A cited regimen is primaquine 30 mg orally daily plus clindamycin 900 mg IV every 8 hours or 600 mg orally every 8 hours. IV pentamidine is dosed at 4 mg/kg once daily, with reduction to 3 mg/kg once daily if toxicity develops. [16][18][21]
- Preferred regimen: TMP-SMX 15–20 mg/kg/day of trimethoprim, divided three or four times daily, orally or IV for 21 days. [16][17][20]
- Mild-to-moderate alternative: atovaquone 750 mg orally twice daily; reserve for patients in whom efficacy tradeoffs are acceptable. [16][19]
- Moderate-to-severe alternative: clindamycin-primaquine or IV pentamidine; avoid aerosolized pentamidine for treatment. [17][19]
- For a mild TMP-SMX allergy, desensitization may be attempted; do not use desensitization after a severe allergy. [20]

*Anti-Pneumocystis treatment selection in adults. [16][17][18][19][20][21]*

| Clinical setting | Regimen | Key safety or selection issue |
| --- | --- | --- |
| Any severity; TMP-SMX tolerated | TMP-SMX: trimethoprim 15–20 mg/kg/day plus sulfamethoxazole 75–100 mg/kg/day in divided oral or IV doses for 21 days. [16][17][20] | Monitor potassium, renal function, blood counts, hepatic tests, and cutaneous toxicity. [17][21] |
| Mild-to-moderate disease; unable to take TMP-SMX | Atovaquone 750 mg orally twice daily, or dapsone-trimethoprim, or clindamycin-primaquine. [16][17][19] | Atovaquone is less effective than TMP-SMX; check G6PD status before primaquine. [19][21] |
| Moderate-to-severe disease; unable to take TMP-SMX | Clindamycin-primaquine or pentamidine 4 mg/kg IV daily; reduce pentamidine to 3 mg/kg daily if toxicity develops. [16][17][18] | Screen for G6PD deficiency before primaquine; pentamidine was associated with poorer outcomes than TMP-SMX or clindamycin-primaquine in an HIV cohort, likely influenced by treatment selection and illness severity. [18][23] |

## Use adjunctive corticosteroids for hypoxemic HIV-associated PJP

Steroid benefit is established most clearly in HIV-associated PJP with hypoxemia.

For nonpregnant adults with HIV-associated PJP, add corticosteroids when room-air PaO2 is below 70 mm Hg or the A-a oxygen gradient is at least 35 mm Hg. Oxygen saturation below 92% on room air is also a practical marker of hypoxemia requiring ABG-based severity assessment. Start prednisone within 72 hours of beginning anti-Pneumocystis therapy, or as soon as possible thereafter. [16][17]

Use prednisone 40 mg orally twice daily on days 1–5, 40 mg once daily on days 6–10, then 20 mg once daily on days 11–21. IV methylprednisolone is an alternative when oral administration is not feasible. [16]

For non-HIV PJP, do not prescribe adjunctive corticosteroids routinely solely by extrapolation from HIV trials. Select hypoxemic patients may benefit, but the evidence base does not establish a universal indication; weigh the potential pulmonary benefit against competing infection risks and the patient’s existing immunosuppressive regimen. [17]
- HIV plus PaO2 <70 mm Hg or A-a gradient ≥35 mm Hg: give early adjunctive prednisone. [16][17]
- Non-HIV PJP: make corticosteroid use case by case rather than routine. [17]

*Adjunctive corticosteroid regimen for hypoxemic HIV-associated PJP. [16][17]*

| Treatment interval | Prednisone regimen | Decision point |
| --- | --- | --- |
| Days 1–5 | 40 mg orally twice daily. [16] | Use when PaO2 is <70 mm Hg or A-a gradient is ≥35 mm Hg; begin within 72 hours of anti-Pneumocystis therapy. [16][17] |
| Days 6–10 | 40 mg orally once daily. [16] | Continue taper if clinical course permits. [16] |
| Days 11–21 | 20 mg orally once daily. [16] | Complete with the 21-day anti-Pneumocystis treatment course. [16][17] |

## Use TMP-SMX prophylaxis in HIV when CD4 thresholds indicate risk

Prophylaxis decisions in HIV are driven by CD4 count, clinical markers of advanced immunosuppression, and feasibility of monitoring.

In adults with HIV, initiate PJP prophylaxis for CD4 count below 200 cells/µL, CD4 percentage below 14%, or oropharyngeal candidiasis. Consider prophylaxis at CD4 200–250 cells/µL when antiretroviral therapy cannot be initiated promptly or CD4 monitoring every three months is not feasible. TMP-SMX is the preferred preventive agent. [20]

A cited TMP-SMX prophylaxis regimen is one single-strength or double-strength tablet orally daily, or one double-strength tablet three times weekly. Daily double-strength TMP-SMX may be preferred when prophylaxis is also intended to cover toxoplasmosis or selected bacterial infections. Review concurrent ACE inhibitor, ARB, or spironolactone use because of hyperkalemia risk. [21]

After acute PJP therapy, reassess immune recovery strategy and the continuing indication for prophylaxis. In patients receiving TMP-SMX treatment or prophylaxis, use serial CBC, creatinine, and potassium measurements to identify cytopenias, renal toxicity, and hyperkalemia before they force an unplanned regimen change. [17][20][21]
- HIV CD4 <200 cells/µL, CD4 percentage <14%, or oral candidiasis: prescribe PJP prophylaxis. [20]
- Preferred prophylaxis options: TMP-SMX one single-strength or double-strength tablet daily, or one double-strength tablet three times weekly. [21]
- Check potassium especially when TMP-SMX is combined with an ACE inhibitor, ARB, or spironolactone. [21]

*HIV-associated PJP prophylaxis triggers and regimens. [20][21]*

| Trigger | Prophylaxis action | Practical consideration |
| --- | --- | --- |
| CD4 <200 cells/µL or CD4 percentage <14% | Start TMP-SMX prophylaxis. [20] | Use daily single-strength or double-strength TMP-SMX, or double-strength TMP-SMX three times weekly. [21] |
| Oropharyngeal candidiasis | Start TMP-SMX prophylaxis regardless of the stated CD4 threshold. [20] | Assess for other opportunistic infections and ART readiness. [20] |
| CD4 200–250 cells/µL with delayed ART or inability to monitor CD4 every 3 months | Consider TMP-SMX prophylaxis. [20] | Monitor creatinine, potassium, and blood counts during therapy. [17][20][21] |

## Common questions

### Can a positive Pneumocystis PCR alone diagnose PJP?

No. PCR is highly sensitive and can detect colonization. Diagnose PJP by integrating compatible pulmonary disease, immunocompromised host status, imaging, respiratory specimen type and quantitative burden when available, β-D-glucan, and exclusion or identification of competing causes. [1][6][8][15]

## References
1. A New Noninvasive Testing Strategy for Pneumocystis jirovecii Pneumonia | NEJM Clinician — clinician.nejm.org — https://clinician.nejm.org/new-noninvasive-testing-strategy-pneumocystis-jirovecii-pneumonia-CLINjwNA59878
2. Abstracts : Journal of Clinical Infectious Disease Society — journals.lww.com — https://journals.lww.com/cids/fulltext/2025/07000/abstracts.10.aspx
3. Expanding the Discussion on Pneumocystis... : Transplant Infectious Disease — journals.lww.com — https://journals.lww.com/00128378-202608000-00030
4. The Saudi Thoracic Society evidence-based... : Annals of Thoracic Medicine — journals.lww.com — https://journals.lww.com/aotm/_layouts/15/oaks.journals/downloadpdf.aspx?an=01284540-202510000-00001
5. Molecular diagnosis of Pneumocystis pneumonia in... — journals.lww.com — https://journals.lww.com/co-infectiousdiseases/fulltext/2019/08000/molecular_diagnosis_of_pneumocystis_pneumonia_in.5.aspx
6. Quantitative real-time PCR and the (1 → 3)-β-d-glucan assay for differentiation between Pneumocystis jirovecii pneumonia and colonization - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1198743X14641562
7. Accuracy of a routine real-time PCR assay for the diagnosis of Pneumocystis jirovecii pneumonia - ScienceDirect — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0167701208002364
8. A prospective comparison of fungal load in paired sputum and bronchoalveolar lavage fluid for Pneumocystis pneumonia diagnosis: Clinical thresholds and diagnostic accuracy — www.sciencedirect.com — https://www.sciencedirect.com/science/article/pii/S1684118225001847
9. Polymerase Chain Reaction-Based Detection of Pneumocystis jirovecii in Bronchoalveolar Lavage Fluid for the Diagnosis of Pneumocystis Pneumonia — www.sciencedirect.com — https://www.sciencedirect.com/science/article/abs/pii/S0002962915311770
10. Advice on the designation of antimicrobials or groups of — www.ema.europa.eu — https://www.ema.europa.eu/en/documents/regulatory-procedural-guideline/advice-designation-antimicrobials-or-groups-antimicrobials-reserved-treatment-certain-infections-humans-relation-implementing-measures-under-article-375-regulation-eu-20196-veterinary-medicinal_en.pdf
11. Pneumocystis Pneumonia: Adult and Adolescent OIs | NIH — clinicalinfo.hiv.gov — https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/pneumocystis
12. Pneumocystis jirovecii Pneumonia: Pediatric OIs | NIH — clinicalinfo.hiv.gov — https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-pediatric-opportunistic-infections/pneumocycstis-jirovecii-pneumonia
13. Guidelines for the Prevention and Treatment of Opportunistic ... — clinicalinfo.hiv.gov — https://clinicalinfo.hiv.gov/sites/default/files/guidelines/archive/adult-adolescent-oi-2025-04-23.pdf
14. Introduction: Adult and Adolescent OIs HIV Clinical Guidelines | NIH — clinicalinfo.hiv.gov — https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-opportunistic-infections/introduction
15. Positive Pneumocystis jirovecii Sputum PCR Results with Negative Bronchoscopic PCR Results in Suspected Pneumocystis Pneumonia - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/29849833
16. Pneumocystis jiroveci Pneumonia: A Review of Management in Human Immunodeficiency Virus (HIV) and Non-HIV Immunocompromised Patients — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10038753
17. When should I give corticosteroids to my patient with Pneumocystis pneumonia? | Cleveland Clinic Journal of medicine — www.ccjm.org — https://www.ccjm.org/content/91/4/217
18. Management of Pneumocystis Jirovecii pneumonia in HIV infected patients: current options, challenges and future directions — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC3218692
19. Therapy and Management of Pneumocystis jirovecii Infection — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC6313306
20. Pneumocystis jirovecii Pneumonia - StatPearls - NCBI Bookshelf — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/books/NBK482370
21. Pneumocystis jirovecii pneumonia in people living with HIV: a review - PMC — pmc.ncbi.nlm.nih.gov — https://pmc.ncbi.nlm.nih.gov/articles/PMC10938896
22. Treatment of Pneumocystis jirovecii pneumonia in HIV-infected patients: a review - PubMed — www.ncbi.nlm.nih.gov — https://www.ncbi.nlm.nih.gov/pubmed/28782390
23. Clinical efficacy of first- and second-line treatments for HIV-associated Pneumocystis jirovecii pneumonia: a tri-centre cohort study - PubMed — www.ncbi.nlm.nih.gov — http://www.ncbi.nlm.nih.gov/pubmed/19858161
24. Pneumocystis jirovecii  Pneumonia in Patients... : Transplant Infectious Disease — journals.lww.com — https://journals.lww.com/00128378-202608000-00031

## Editorial note

Prepared from cited clinical literature using Astra's research workflow. Verify recommendations against current guidance and patient-specific factors.